Press release: SATT Nord and Apmonia Therapeutics have entered into agreements in which Apmonia Therapeutics has been granted an exclusive worldwide license for the development and commercialization of the innovative anti-cancer immunotherapy (TAX2 peptide).
#immunotherapy #fightcancer #peptide
